Surgical Innovations Group Plc
("Surgical Innovations", the "Company" or the "Group")
Directorate Change
Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, announces that Paul Hardy, having entered his ninth year as a Director, has notified the Board of his intention to step down from his position of Independent Non-executive Director ("NED") at the Company's AGM which is expected to be held in June this year.
Paul chairs the Audit Committee and will retain this position until he steps down. The Board will begin an extensive search for a replacement NED to ensure orderly succession and will provide further updates in due course.
CEO, David Marsh, commented: "I would like to thank Paul for his dedication to Surgical Innovations over his tenure as a NED for the Company. His contribution to the Company has been invaluable and I wish him well for the future."
For further information please contact:
Surgical Innovations Group plc |
|||
David Marsh, CEO Charmaine Day, CFO |
Tel: 0113 230 7597 |
||
|
|
||
Singer Capital Markets (Nominated Adviser & Broker) |
Tel: 020 7496 3000 |
||
Aubrey Powell / Alex Bond / Oliver Platts |
|
||
|
|
||
Walbrook PR (Financial PR & Investor Relations) |
Tel: 020 7933 8780 or si@walbrookpr.com |
||
Paul McManus / Charlotte Edgar / Alice Woodings |
Mob: 07980 541 893 / 07884 664 686 / 07407 804 654 |
||
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the
Elemental also has exclusive
In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.
Further information
Further details of the Group's businesses and products are available on the following websites:
To receive regular updates by email, please contact si@walbrookpr.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.